In Brief Abud et al. describe a fully defined protocol for the generation of human iPSC-derived microglia-like cells (iMGLs). Whole-transcriptome and novel functional analyses were used to validate microglial identity. iMGLs provide a platform for studying microglial function in health and disease.
INTRODUCTION
Microglia are the innate immune cells of the CNS and play important roles in synaptic plasticity, neurogenesis, homeostatic functions, and immune activity. Microglia also play a critical role in neurological disorders, including Alzheimer's disease (AD), highlighting the need to improve our understanding of their function in both health and disease. Yet, studying human microglia is challenging because of the rarity and difficulty in acquiring primary cells from human fetal or adult CNS tissue. Therefore, there is a pressing need to develop a renewable source of human microglia, such as from induced pluripotent stem cells (iPSCs).
The challenges of generating microglia from iPSCs are due to their unique developmental origin. Elegant lineage tracing studies show that microglia originate from yolk sac erythromyeloid progenitors (EMP) generated during primitive hematopoiesis (Ginhoux et al., 2010; Kierdorf et al., 2013; Schulz et al., 2012) . EMPs further develop to early primitive macrophages that migrate into the developing neural tube and become microglial progenitors (Kierdorf et al., 2013; Prinz and Priller, 2014) . Microglia progenitors then mature and develop ramified processes used to survey their environment, facilitate CNS development, modulate synaptic plasticity, and respond to CNS injury and pathology. Recently, murine studies identified key cytokines, cell receptors, and transcription factors required for microglia development and survival in vivo. These factors include IL-34 and TGFb1 Greter et al., 2012; Wang et al., 2012; Yamasaki et al., 2014) . We hypothesized that iPSCs could be differentiated to human microglia in vitro by providing cues that mimic the environment present in the developing embryo.
The generation of patient-derived iPSCs has facilitated new opportunities to examine the relationships between genetic risk factors and disease. Recently, genome-wide association studies (GWASs) have identified several genes expressed by + iHPCs for 10 days and then cultured in serum-free microglia differentiation media containing human recombinant MCSF, IL-34, and TGFb-1 (i). Differentiation is carried out for an additional 25 days after which iMGLs are exposed to human recombinant CD200 and CX3CL1 for 3 days. Representative image of iHPCs in cell culture at day 10 (ii). Scale bar, 100 mm. By day 14, iMGLs express PU.1 (green) and TREM2 (red) (iii). Scale bar, 50 mm. Representative phase contrast image of iMGL at day 38 (iv).
(B) Schematic of differentiation of iPSCs to iHPCs. Single-cell iPSCs are differentiated in a chemically defined media supplemented with hematopoietic differentiation factors and using 5% O 2 (4 days) and 20% O 2 (6 days) (i). After 10 days, CD43 + iHPCs are CD235a (legend continued on next page) microglia that are associated with the risk of developing lateonset AD (LOAD), such as TREM2 and CD33. The role of these genes in microglial function and AD is just beginning to be examined in mouse models, but the generation of human microglialike cells would allow for the interrogation of human-specific genes that cannot be modeled in mice. In AD, microglia cluster around b-amyloid plaques highlighting their inability to clear b-amyloid (Hickman et al., 2008; Liu et al., 2010) . Microglia are also implicated in the neuroinflammatory component of AD etiology, including cytokine/chemokine secretion, which exacerbates disease pathology (Guillot-Sestier and Town, 2013) . Furthermore, microglia-expressed AD-GWAS genes, like TREM2 and CD33, likely play a role in AD progression. Thus, there is a pressing need to further our understanding of human microglia and the influence of both pathology and disease-associated genes on microglial function. Addressing this critical need, we report the effective and robust generation of human iPSC microglial-like cells (iMGLs) that resemble fetal and adult microglia and demonstrate their utility in investigating neurological diseases like AD.
RESULTS
Human Microglia-like Cells Are Generated from iPSCs A two-step fully defined protocol was developed to efficiently generate microglia-like cells from iPSCs in just over 5 weeks ( Figure 1A ). This approach was used to successfully produce iMGLs from ten independent iPSC lines (Figures S1A-S1C). A critical prerequisite is the robust differentiation of iPSCs to hematopoietic progenitors (iHPCs). This recapitulates microglia ontogeny as iHPCs represent early primitive hematopoietic cells derived from the yolk sac that give rise to microglia during development (Ginhoux et al., 2010; Kierdorf et al., 2013) . Our protocol (depicted in Figure 1Bi ) yields primitive iHPCs that are CD43 + /CD235a + /CD41 + after 10 days (Kennedy et al., 2007; Sturgeon et al., 2014) . Fluorescence-activated cell sorting (FACS) for CD43 + cells reveal that our approach produces iHPCs with a >90% purity (Figure 1Bii ). The resulting iHPCs resembled a commercial source (Cellular Dynamics International) and represent the hematopoietic progenitor used to generate iMGLs.
Next, CD43 + iHPCs were grown in serum-free differentiation medium (formulated in house) containing CSF-1, IL-34, and TGFb1. By day 14, cells expressed the myeloid-associated transcription factor PU.1 and the microglia-enriched protein TREM2 (Figure 1Aiii ), demonstrating an early commitment toward microglial fate. Because this protocol yields large amounts of iMGLs, microglia development was studied in vitro as cells could be characterized every 4 days by flow cytometry. Day 14 early iMGLs were c-kit (Kierdorf et al., 2013) . CD45 expression was consistently monitored in developing iMGLs and compared to monocyte-derived macrophages (MD-M4). While CD45 expression increased with maturation, levels never reached that of macrophages ( Figure 1D ), consistent with murine development (Kierdorf et al., 2013) . A small population of iMGLs ($10%) also expressed intermediate CD11b levels by day 14 that also increased as cells matured but again never reached macrophage levels ( Figures 1E and 1F) . By day 38, iMGLs resemble human microglia, but not monocytes nor macrophages, by cytospin/Giemsa staining ( Figure 1G ) and express many other microglial-enriched proteins, including MERTK, ITGB5, CX3CR1, TGFbR1, and PROS1 ( Figures 1H; Figure S4) . Like murine microglia development in vivo, iMGLs developing in vitro express PU.1, TREM2, and CD11b int /CD45 low . As iMGLs mature in vitro, they also become more ramified, similar to microglia in vivo (Figures 1Aiv and 1H) . Furthermore, purinergic receptor P2RY12 and TREM2 co-expression was enriched in iMGLs when compared to monocytes and quantification reveals that our protocol yielded iMGLs of high purity (>97.2%, n = 5) ( Figure 1I ; Figures S2A and S2B).
Genomic integrity was also maintained over the course of differentiation. Assessing copy number variants across all chromosomes demonstrated that extra chromosomal fragments were not acquired by iMGLs when compared to their respective iPSCs (n = 6, Figures S1D and S1E). A comparison of a representative differentiation across the entire probeset (n = 383, nCounter Human Karyotype Panel) revealed a high correlation between the iPSC and iMGL genomes (r 2 > 0.92, Figure S1F ). Importantly, this protocol typically yielded 30-40 million iMGLs from one million iPSCs, suggesting that our approach can be readily scaled up for high content screening. All iPSC work was performed with approval from the appropriate University of California, Irvine oversight committee (see STAR Methods). (Figure 2A ; Figure S3A ). We confirmed that myeloid, hematopoietic, and stem cells used in correlation and PCA analyses expressed lineage-specific markers ( Figure S3B ). Furthermore, the first principal component PC1 (21.3% variance, Figure 2A , arrows) defines the differentiation time series from iPSC through iHPC to our iMGL cells while PC2 and PC3 define the dendritic and monocyte trajectories, respectively. Biclustering analysis using 300 microglial, (G) Mary-Grunwald Giemsa stain of monocytes, MD-M4, fetal microglia, and iMGLs. Both fetal microglia and iMGL exhibit a high nucleus to cytoplasm morphology compared to monocytes and MD-M4. Scale bars, 16 mm.
(H) iMGLs also exhibit extended processes and express CX3CR1 (green) together with the human cytoplasmic marker (hCyto, SC121; red).
(I) Differentiation yields >97.2% purity as assessed by co-localization of microglial-enriched protein P2RY12 (green), microglial-enriched TREM2 (red), and nuclei (blue; n = 5 representative lines). See also Figures S1 and S2.
macrophage, and other immune-related genes adapted from previous studies Hickman et al., 2013; Zhang et al., 2014) identified similarities between groups and highlighted common gene clusters but also uncovered differences between all groups. Again, this analysis showed that iMGLs cluster with microglia but are distinct from other myeloid Hickman et al., 2013; Zhang et al., 2014) . A pseudo-count was used for FPKM values (FPKM +1), log 2 -transformed, and each gene was normalized in their respective row (n = 300). Representative profiles are shown for genes up-and downregulated in both human microglia (fetal/adult) and iMGLs.
(C) Bar graphs of microglial-specific or -enriched genes measured in iMGL, Fetal and Adult MG, Blood DC, CD14 M, and CD16 M as [Log 2 (FPKM +1)] presented as mean ± SEM. Data were analyzed using one-way ANOVA followed by Tukey's corrected multiple comparison post hoc test. Statistical annotation represents greatest p value for iMGL, Fetal MG, and Adult MG to other myeloid cells. CD14 M (n = 5), CD16 M (n = 4), Blood DC (n = 3), iMGL (n = 6), Fetal MG (n = 3), and Adult MG (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Complete statistical comparisons are provided in Table S1 . See also Figures (legend continued on next page) cells, iHPCs, and iPSCs ( Figure 2B ). All studies using human tissue were approved by the appropriate institutional review board (see STAR Methods). Importantly, iMGLs, Fetal MG, and Adult MG express canonical microglial genes, such as P2RY12, GPR34, C1Q, CABLES1, BHLHE41, TREM2, ITAM PROS1, APOE, SLCO2B1, SLC7A8 , PPARD, and CRYBB1 ( Figure 2C ; Table S1 ). When compared to monocytes, iMGLs express the myeloid genes RUNX1, PU.1, and CSF1R are enriched for P2RY12, OLFML3, and GPR34 yet do not express monocyte-specific transcription factors IRF1, KLF4, and NR4A1 (Abdollahi et al., 1991; Hanna et al., 2011; Lavin et al., 2014) (Figures S3C-S3E ). Differential analysis between iMGLs, CD14 M, and CD16 M ( Figure S3F) (Tables S4-S6 ). These terms reflect expected processes in which iMGLs are cued to respond to the environment and possess a capacity for renewal and maturation that have previously been reported in cultured microglia . Differential gene expression analysis between Fetal MG and Adult MG identified pathways related to responses to environment, like migration and phagocytosis regulation, but not key myeloid genes in Fetal MG. Adult MG enrichment includes electron cryomicroscopy (ECM) organization, nervous system regulation, cell adhesion, and negative regulation of cell proliferation.
Functional Validation of iMGLs
Next, iMGLs were validated as surrogates of microglia using both functional and physiological assays. By flow cytometry analysis, iMGLs were CD11b int /CD45 lo-int , similar to Fetal MG ( Figures 3A  and 3B ). Next, cytokine/chemokine secretion by iMGLs was measured following stimulation by lipopolysaccharide (LPS), IL-1b, or IFNg. IL-1b and IFNg are two cytokines that are elevated in AD patients and mouse models (Abbas et al., 2002; Blum-Degen et al., 1995; Marsh et al., 2016; Patel et al., 2005; Wang et al., 2015) ( Figure 3C ). Basally, iMGLs secrete ten of the examined cytokines at low, but detectable, levels (Table S2 ). However, in response to IFNg or IL-1b, iMGLs secrete eight different chemokines, including TNFa, CCL2, CCL4, and CXCL10. As expected, iMGLs robustly responded to LPS with induction of all measured cytokines except for CCL3 (Table S2 for values). Collectively, iMGLs differentially release cytokines/chemokines based on their cell surface receptor stimuli, a finding that closely aligns with the responses observed in acutely isolated primary microglia (Rustenhoven et al., 2016) .
iMGLs express the microglial-enriched purinergic receptor P2RY12, which sense extracellular nucleotides from degenerating neurons, and is critical for microglial homeostatic function Moore et al., 2015) (Figures S2A and S2B) . In response to ADP, iMGLs chemotax toward ADP and produce detectable calcium transients ( Figures 3D and 3E ) that were both negated by a P2RY12-specific inhibitor, PSB0739. These physiological findings further underscore that iMGLs respond appropriately to stimuli and express functional surface receptors, such as P2RY12, enabling quantitative analyses of microglial physiology.
Microglia, like astrocytes, play a critical role in synaptic pruning (Aguzzi et al., 2013; Paolicelli et al., 2011; Stephan et al., 2012) . Because in vitro synaptosome phagocytosis assays are an established surrogate to study pruning, the ability of iMGLs to phagocytose human synaptosomes (hS) was quantitatively assessed. In comparison to MD-M4, iMGL phagocytosis of pHrodo-labeled hS was less robust (Figures 3F and 3G ). However, iMGLs preferentially internalized hS when compared to E. coli particles and normalized to MD-M4 ( Figures S4D and  S4E ), supporting the notion that iMGLs and microglia are more polarized toward homeostatic functions than MD-M4.
As iMGLs and primary microglia express both C1q and CR3 (CD11b/CD18 dimer), iMGLs were used to assess whether synaptic pruning in human microglia primarily involves this pathway as seen in mice (Hong et al., 2016a (Hong et al., , 2016b . Using an additivefree CD11b antibody, iMGL phagocytosis of hS was significantly by inhibiting CR3 via CD11b blockade. Bottom: sub-analysis of iMGLs exhibiting a phagocytic event reveals similar average amounts of internalization across treatment groups (p = 0.1165). All histograms reported as mean ± SEM. Cytokine and migration assays one-way ANOVA, followed by Dunnett's multiple comparison post hoc test, ***p < 0.0001, **p < 0.001, *p < 0.05; Cytokine assay: n = 3 wells/group. Migration assay: n = 5 fields/condition. Calcium assay: vehicle (n = 37 cells), PSB0739 treated (n = 17 cells), I 340 /I 380 represented as mean ± SEM at each time point. Phagocytosis assay: MD-M4 versus iMGL: unpaired t test, **p < 0.001, n = 3 wells/group. MERTK and CR3 assay, one-way ANOVA, followed by Tukey's multiple comparison post hoc test, ***p < 0.0001; n = 6 for vehicle, n = 3 wells/group. See also Figure S4 . reduced (À40.0%, ***p < 0.0001) (Figures 3H and 3I) . In contrast, an inhibitor of MERTK (UNC569), also implicated in synaptic pruning, only marginally decreased iMGL hS phagocytosis (À12.6%, *p < 0.05) (Figures 3H and 3I) . Similar to studies in murine knockout (KO) models, our data indicate that MERTK plays a minor role in human microglia-mediated synaptic pruning (Chung et al., 2013) , whereas C1q/CR3 is integral for microglia-mediated synaptic pruning in humans.
Utility of iMGLs to Study Alzheimer's Disease
Impaired microglia clearance of b-amyloid (Ab) is implicated in the pathophysiology of AD and strategies to enhance clearance (C) iMGLs were exposed to unlabeled fAb (5 mg/mL À1 ) and BDTOs (5 mg/mL) for 24 hr, and mRNA expression of 19 GWAS genes was assessed via qPCR array. fAb treatment elevated the expression of 10 genes above 2-fold compared to vehicle, including MS4A6A (6.3-fold), CD33 (6.1-fold), ABCA7 (5.8-fold), TYROBP (4.98-fold), and TREM2 (4.85-fold). Whereas, BDTO exposure elevated the expression of four genes above 2-fold compared to vehicle. Six genes were differentially expressed in fAb compared to BDTO. Both fAb and BDTO preparations were confirmed via dot blot analysis with conformation structural specific antibodies for oligomers (A11), fibrils (OC), and non-structural-specific antibodies for human Ab (6E10) and tau oligomers (Tau22). Target genes were normalized to GAPDH and compared to vehicle expression by DDCt. Bars show expression fold mean ± SEM. Red hash bar is DDCt = 1. Two-way ANOVA, followed by Sidak's multiple comparison post hoc test, ***p < 0.0001, **p < 0.001, *p < 0.05; n = 6 wells/group. Data represented as mean ± SEM. See also Figures S5 and S6.
of AD pathology are being actively pursued by biopharma. Therefore, we examined whether iMGLs can phagocytose Ab or tau, two hallmark AD pathologies. Like primary microglia, iMGLs internalize fluorescently labeled fibrillar Ab (fAb) (Figure 4B) . iMGLs also recognized and internalized pHrodo-labeled brain-derived tau oligomers (BDTOs) ( Figure 4B ). Fluorescence emitted indicates trafficking of pHrodo-conjugated BDTOs to the acidic lysosomal compartment, showing that iMGLs can actively ingest extracellular tau that may be released during neuronal cell death (VillegasLlerena et al., 2016) and support recent findings that microglia may play a role in tau propagation in AD and other tauopathies (Asai et al., 2015) . Together, these findings suggest that iMGLs could be utilized to identify compounds in high-throughput drug-screening assays that enhance Ab degradation or block exosome-mediated tau release.
Microglia genes are implicated in late-onset AD, yet how they modify disease risk remains largely unknown. Thus, iMGLs were utilized to begin investigating how these genes might influence microglia function and AD risk. Hierarchical clustering using just these 25 AD-GWAS genes also demonstrates that iMGLs resemble microglia and not peripheral myeloid cells ( Figure 4A ). In their investigated basal state, iMGLs and microglia express many AD-GWAS-related genes, including those without murine orthologs, i.e., CD33, MS4A4A, and CR1. Thus, iMGLs can be used to study how altered expression of these genes influence microglia phenotype in a way that cannot be recapitulated in transgenic mice. Therefore, iMGLs were used to investigate the influence of fAb or BDTOs on AD-GWAS gene expression in microglia (Villegas-Llerena et al., 2016) (Figure 4C ). Following fAb exposure, iMGLs increased expression of ten genes (Table S3), including ABCA7 (5.79 ± 0.44), CD33 (6.02 ± 0.41), TREM2 (4.86 ± 0.50), and APOE (2.52 ± 0.19), genes implicated in Ab clearance/degradation. BDTOs increased expression of four genes, including CD2AP (4.62 ± 0.45), previously implicated in tau-mediated toxicity (Shulman et al., 2014) . In addition, six genes were differentially elevated in fAb compared to BDTOs (Table S3) . Interestingly, CD33, TYROBP, and PICALM, genes more enriched in other myeloid cells at baseline, were upregulated by fAb and BDTOs, suggesting that proteinopathies may alter microglia phenotype to resemble invading peripheral myeloid cells (Chan et al., 2007; Prinz et al., 2011; Stalder et al., 2005) . In addition to AD-GWAS genes, iMGLs express other CNS disease-related genes, including APP, PSEN1/2, HTT, GRN, TARDBP, LRRK2, C9orf72, SOD1, VCP, and FUS, and therefore can likely be used to study other neurological diseases, such as amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), frontal temporal dementia (FTD), and dementia with Lewy bodies (DLB), in which microglia may play a prominent role (Bachstetter et al., 2015; Crotti et al., 2014; Lui et al., 2016; O'Rourke et al., 2016) (Figure S6C ).
iMGL Maturation and Homeostasis Are Modulated by a CNS Environment
Neurons, astrocytes, and endothelial cells in the brain interact with microglia to influence gene expression and function. Our differentiation protocol attempted to recapitulate CNS cues present in the brain by including signals derived from these other cell types, including CX3CL1, CD200, and TGFb. Whole-transcriptome RNA sequencing (RNA-seq) analysis confirmed the importance of these factors for establishing microglia in vitro ( Figures S5 and S6 ). TGFb, a glia-derived cytokine, is needed for murine microglia development in vivo and in maintaining the microglial-specific transcriptome signature (Abutbul et al., 2012; Butovsky et al., 2014; Schilling et al., 2001) . Differential gene expression analysis confirmed TGFb's role in maintaining the human microglia transcriptome signature; 1,262 genes were differentially expressed in iMGLs with TGFb, whereas 1,517 genes were differentially expressed in iMGLs after TGFb removal (24 hr). Many of the differentially expressed genes are identified as core microglial signature targets, including P2RY12, TGFbR1, and CD33, and transcription factors EGR1, ETV5, and APOE ( Figures S5A-S5C ). Examination of gene ontology highlight neurodegenerative disease pathways, including Alzheimer's, Parkinson's, and Huntington's diseases, that are TGFb dependent ( Figure S5D ). Furthermore, removal of TGFb led to significant changes in many of the human microglia homeostatic targets also identified as AD-GWAS loci genes, including TREM2, APOE, ABCA7, SPI1 (CELF1 locus), PILRA (ZCWPW1 locus), and the HLA-DR and MS4A gene clusters (Karch et al., 2016) , suggesting many identified AD-GWAS genes function in the maintenance of microglia homeostasis (Figure S5E ) and underscoring the utility of iMGLs to interrogate AD-GWAS gene function.
CX3CL1 and CD200 are both neuronal-and endothelialderived cues that can further educate iMGLs toward an endogenous microglia phenotype (reviewed in Kierdorf and Prinz, 2013) . To test this hypothesis, we examined how inclusion or exclusion of these factors modulates iMGL phenotype. The addition of CD200 and CX3CL1 to iMGLs increased the expression of select genes like COMT (Bennett et al., 2016) (Figure S5B ), CD52, a cell surface receptor that binds Siglec10 and interacts with DAP12 as part of the microglia sensome (Hickman et al., 2013) , and HLA-DRB5, a member of the MHC II complex implicated in AD, while maintaining similar expression levels of core-microglial genes (e.g., P2RY12, TYROBP, and OLFML3) and AD risk genes ( Figure S6A ). Importantly, we found that CD200 and CX3CL1 modulated iMGL response to CNS stimuli, such as fAb. In the absence of CD200 and CX3CL1, fAb stimulated the expression of AD-GWAS genes implicated in interacting with misfolded folded protein, surface receptors, or anti-apoptotic events, such as CLU (APOJ) (Yeh et al., 2016) . Whereas cells exposed to these two factors responded differentially to fAb, increasing expression of genes involved in neuronal cell surface motif recognition, or phagocytosis of CNS substrates, including MS4A genes, TREM2, TYROBP, CD33, and ABCA7 (Bradshaw et al., 2013; Fu et al., 2016; Greer et al., 2016) (Figure S6B ). These studies further support the notion that CD200-CD200R1 and/or CX3CL1-CX3CR1 axis can prime microglia to respond to neurodegenerative conditions (Prinz and Priller, 2014) . Thus, exposure to soluble CNS factors, like CD200 and CX3CL1, may allow for access to microglial-specific transcriptional regulator elements (enhancers and promoters) Lavin et al., 2014) , although future studies are required to fully translate these observations. Next, we examined whether iMGL maturation can be achieved with direct contact with the CNS environment. Therefore, iMGLs were cultured with rat hippocampal neurons (21 days in vitro [DIV] ) to assess how iMGLs respond to neuronal surface cues ( Figure 5A ). Rat hippocampal neurons were used because they readily form synapses in culture and can be generated with limited variability. iMGLs were subsequently separated from neurons by FACS with human-specific CD45 and CD11b antibodies and profiled at the transcriptome level ( Figure 5B ). Differential gene expression analysis revealed that neuronal co-culturing upregulated 156 and downregulated 244 iMGL genes ( Figures 5C and 5D ). FFAR2 and COL26A1 are two genes differentially expressed in iMGLs cultured with only defined factors and indicate a developmentally primed microglia profile. In contrast, co-culturing microglia with neurons increased expression of SIGLEC11 and SIGLEC12, human-specific sialicacid binding proteins that interact with the neuronal glycocalyx, function in neuroprotection, and suppress pro-inflammatory signaling, and thus maintain a microglia homeostatic state (Linnartz-Gerlach et al., 2014; Wang and Neumann, 2010) . Additionally, we saw increased expression of microglial genes CABLES1, TRIM14, MITF, MMP2, and SLC2A5. Overall, these results implicate both soluble and surface CNS cues as factors in microglia maturation (Biber et al., 2007) (Figures 5E and 5F) .
A fundamental characteristic of microglia is the surveillance of the CNS environment with their highly ramified processes. To investigate how iMGLs might interact within a human brain environment and to test whether iMGLs invade BORGs similarly to how microglia enter the developing neural tube (Chan et al., 2007; Rezaie and Male, 1999) , we cultured iMGLs with hiPSC 3D brain organoids (BORGs). BORGs include neurons, astrocytes, and oligodendrocytes that self-organize into a corticallike network but lack microglia ( Figure 6 ). By day 3, iMGLs had embedded into the BORGS and were not detected in the media, suggesting rapid iMGL chemotaxis toward CNS cues ( Figures 6A-6C) . By day 7, iMGLs (green) also tiled and extended varying degrees of ramified processes within the 3D organoid environment (Figures 6D-6F ). To determine whether iMGLs respond to neuronal injury, we pierced BORGS with a 25G needle. After injury, iMGLs clustered near the injury site and adopted a more amoeboid morphology, resembling ''activated'' microglia found in injured or diseased brains (Kettenmann et al., 2011) (Figures 6G-6I) . Collectively, these data demonstrate that iMGLs can integrate within an in vitro 3D CNS environment, mature, ramify, and respond to injury similar to brain microglia.
Next, we sought to examine iMGLs within the context of a CNS environment in vivo. To this end, we transplanted iMGLs (day 38) into the cortex of MITRG mice that are Rag2-deficient and IL2rg-deficient mice and also express the human forms of four cytokines knocked in (M-CSF h ;IL-3/GM-CSF h ;TPO h ), allowing for xenotransplantation and survival of myeloid and other leukocytes (Rongvaux et al., 2014) . 2 months after transplantation, the homeostatic state and identity of transplanted microglia were assessed with P2RY12 and the human-specific TMEM119 antibodies, respectively (Bennett et al., 2016; Butovsky et al., 2014; Haynes et al., 2006) (Figure 7 ). Human-specific markers, Ku80 (hNuclei) and cytoplasmic SC121 (hCyto), distinguished iMGLs from endogenous microglia. Transplanted human iMGLs co-expressing both Ku80 and P2RY12 were abundant within MITRG brains, suggesting long-term engraftment potential (Figures 7A-7D) . At higher magnification, P2RY12 is expressed in highly ramified iMGLs resembling quiescent cortical microglia; the membrane distribution accentuates the finer extended processes ( Figures 7B-7D) (Baron et al., 2014) . TMEM119 and IBA1 were also expressed in both hCyto + soma and in highly arborized iMGL processes ( Figures 7E-7L) . At higher magnification, TMEM119 is predominately membrane bound, in agreement with previous studies (Bennett et al., 2016) . Together, these findings demonstrate engraftment and long-term survival of iMGLs that result in highly branched, microglia-like cells expressing IBA1, P2RY12, and TMEM119 ( Figures  7I-7L ), in which iMGLs resemble endogenous quiescent microglia. Finally, the morphology and high P2RY12 expression suggest that transplanted iMGLs are actively surveying their neuronal environment that translates to their potential use in studying human microglia function in mouse CNS disease models.
To test this hypothesis, we transplanted iMGLs into the hippocampi of xenotransplantation-compatible AD mice, previously generated and characterized in our lab (Marsh et al., 2016) , to examine how iMGLs interact with AD neuropathology in vivo (Figures 7M-7P ; Figure S7 ). Transplanted iMGLs engraft and migrate along white matter tracts, similar to microglia in development ( Figure 7M ). In many instances, iMGLs migrated and extended processes toward Ab plaques to begin walling them off (Figures 7N-7P ; Movie S1). A number of iMGLs also began to phagocytose fibrillar Ab (Figures  7N-7P ; Figures S7E-S7H) . Similarly, human fetal microglia migrated toward Ab, extended processes, and phagocytosed Ab when transplanted in the same AD transgenic model ( Figures S7A-S7D ). (A-L) After 2 months in vivo, iMGLs transplanted into mice display long-term viability with highly arborized processes resembling endogenous microglia found in the brain. Transplanted iMGLs, labeled with P2RY12 (green; HPA HPA014518, Sigma) and human nuclei (Ku80, red), exhibit long-term viability in mice (A). At higher magnification, P2RY12 is highly expressed in iMGL arborized processes, both suggestive of homeostatic microglia surveying the brain environment (B-D). Ramified iMGLs also express microglia-enriched TMEM119 recognized by a human-specific TMEM119 antibody (green; ab185333, Abcam, identified and validated in Bennett et al., 2016 , and human cytoplasm maker SC121 (hCyto, red) (E-H). At higher magnification, representative iMGLs express P2RY12 (green), hCyto (red), and Iba1 (blue; ab5076, Abcam) (I-L).
(M-P) Human iMGLs (hCyto, red) transplanted into AD-immune-deficient mice (Marsh et al., 2016) interact with and phagocytose amyloid plaques (white). Transplanted iMGLs extend projections and migrate to plaques (M and N). iMGLs fully encompass amyloid plaques (O) and begin to phagocytose amyloid (P). Scale bars, 30 mm (A, E, and N), 10 mm (B-D, F-H, I-L, O, and P), and 300 mm (M). n = 3 animals per study. See also Figure S7 .
DISCUSSION
Here, we show that human microglia-like cells can be generated from iPSCs following a fully defined and highly efficient protocol, which enables high purity (>97%) and robust scalability. Importantly, iMGLs are highly similar to cultured human adult and fetal microglia by both transcriptomic and functional analyses. Our whole-transcriptome PCA also highlights the differentiation trajectory of iPSCs toward iHPCs and then iMGLs. Moreover, our series of microglial functional assays, only possible with a high yield and pure protocol, further strengthens how iMGLs can be used to investigate microglia genes implicated in disease and understand physiological function both in vitro and in vivo.
We also demonstrate the use of iMGLs to investigate human microglial function as a therapeutic target in human disease. A recent study implicated complement and increased microgliamediated pruning of synapses early in AD (Hong et al., 2016a (Hong et al., , 2016b . Here, we found that blocking CR3, via anti-CD11b, in iMGLs reduced phagocytosis of human synaptosomes. Our findings provide one of the first examples, to our knowledge, of quantitative evidence showing human microglia engulfing human synaptosomes predominately via the CR3 axis, as implicated by transgenic mouse studies (Hong et al., 2016a) . Moreover, we highlight the utility of iMGLs to examine microglia-targeted AD therapies, such as anti-CD11b, in phagocytic assays and to potentially examine or validate other complement-targeted therapies in development.
Microglia mediate neuroinflammation through surveillance of their environment and by cell surface receptor activation. Therefore, we tested iMGL response to extracellular stimuli observed in AD, such as nucleotides leaked from degenerating neurons. Microglia sense ADP release via purinergic receptors, and we likewise find that iMGLs robustly express functional P2RY12 and migrate and exhibit calcium influx via an ADP-P2RY12 receptor mechanism. Also, iMGLs secrete a variety of cytokines in response to IFNg, IL-1b, and LPS stimulation. Many of these cytokines are known to be highly elevated in neurological diseases and/or involved in the recruitment of peripheral immune cells into the CNS under pathological conditions (Chan et al., 2007; Prinz et al., 2011; Rezaie and Male, 1999; Stalder et al., 2005) . Microglial-mediated cytokine secretion can further influence the inflammatory milieu in the CNS and thus represents an excellent therapeutic target for restoring CNS homeostatic balance. Together, migration, calcium imaging, and cytokine secretion assays not only validate iMGLs to be highly similar to brain-derived microglia, but provide important functional assays to assess the role of microglia in neuroinflammation. Furthermore, our data highlight the potential utility of iMGLs to identify therapeutic compounds via high-throughput assessment of microglia physiology.
Since the discovery of SNPs in immune genes as AD risk factors, microglia have been further highlighted in human neurological health and disease. Several of these AD-GWAS genes, including CD33 and CR1, lack functionally similar murine orthologs. Thus, iMGLs can be utilized to investigate AD-GWAS genes and elucidate their roles in human microglia biology. Ab fibrils upregulated APOE, TREM2, CD33, and APOJ, genes previously implicated in modulating Ab phagocytosis and clearance (Bradshaw et al., 2013; Yeh et al., 2016) . We also found that MS4A6A gene expression was increased. While the role of the MS4A gene cluster in microglia function and AD risk is still unknown, our data suggest a potential role in modulating Ab interactions. Furthermore, CD200 and CX3CL1 were important developmental CNS cues for generating iMGLs that can respond appropriately to Ab. These data implicate these factors in modulating promoter/enhancer regions that enables appropriate responses to stimuli previously shown for macrophages Lavin et al., 2014) (further reviewed in Glass and Natoli, 2016) . Lastly, a TGFb-dependent homeostatic microglia signature was identified that paralleled murine studies and highlight that AD-GWAS genes function in microglia homeostasis. Taken together, our studies emphasize the importance of microglia in AD risk and the utility of iMGLs to interrogate genotypephenotype relationships of recent AD-GWAS single nucleotide polymorphisms.
We also highlight how neuronal co-culture can further modulate microglial gene expression and how interactions with the neuronal glycocalyx increase Siglec expression. Interestingly, iMGLs not cultured with neurons differentially expressed early microglia genes, including FFAR2 (Erny et al., 2015; Matcovitch-Natan et al., 2016) , suggesting that other factors are needed to further educate microglia as tissue-resident macrophages of the brain. In accordance with this notion, iMGLs cultured in 3D brain cultures actively migrate, tile, and encompass the volume of the BORGs, extending processes reminiscent of early microglia development. We also show that iMGLs transplanted in mice, engraft, survive, and display characteristic ramified processes that have increased branch order complexity, closely resembling quiescent microglia (Andreasson et al., 2016) . We also note that transplanted, highly ramified iMGLs were morphological heterogeneous within the brain (Figures 7I-7L ). This morphological diversity is indicative of microglia responding to distinct cortical layers/brain regions and potentially reflect microglia subtypes found within the brain (Grabert et al., 2016) . Our results also demonstrate that iMGLs can respond appropriately to the neurotoxic buildup of Ab, thus providing a model system to investigate the role of microglia in various proteinopathies.
Overall, these results underscore the potential of iMGLs as a renewable source of patient-derived, microglial-like cells for studying the role of microglia in neurodegenerative diseases. While our comparisons were limited to cultured microglia, we showed that our cells were highly similar to primary cells, and our studies have highlighted potential new ways to culture microglia within BORGs or mouse brains. For example, transplantation of iMGLs into various CNS disease mouse models will allow for the study of human microglial function in neurodegenerative disease in vivo that may be influenced by genetics and the inheritance of specific mutations. This platform will allow for the identification of potential novel, microglial-based translational therapies, as recently discussed (Biber et al., 2016) . Finally, while technical challenges exist for isolating microglia from both human brain and BORGS for study, the development of future tools will likely make it feasible to compare microglia isolated from BORGs with freshly isolated microglia to determine whether 3D organoid systems fully recapitulate the in vivo microglia signature. In summary, we demonstrate a methodology to generate human microglial-like cells in large quantities from renewable iPSCs that can be used as primary microglia surrogates.
Our study is one of the first to describe a fully defined, serumfree protocol for generating microglial cells from induced pluripotent stem cells with the exception of a recently published resource from Muffat and colleagues (Muffat et al., 2016) . However, their approach uses hematopoietic cells derived from embryoid bodies (EBs) as microglia precursors. One challenge with the use of an EB-based method and selection by cell adhesion (Muffat et al. 2016 protocol) is the potential contamination by other cell types that spontaneously arise from EBs, i.e., neuroectoderm including astrocytes. More recently, a protocol described the production of microglia-like cells reliant on astrocyte co-cultures and a serum-based media formulation. This protocol produces cell quantities comparable to Muffat et al. (2016) that exhibit amoeboid-like morphology in vitro and in vivo (Pandya et al., 2017) . Thus, some questions remain in terms of yield, scalability, and purity of homeostatic microglia using these other methods and whether the resulting cells can be used to interrogate microglial function in quantitative assays that require large numbers of pure microglia-like cells.
In summary, we have developed a highly reproducible protocol to generate iPSC-derived hematopoietic progenitor cells and microglia-like cells in high yield that can be used in functional assays to interrogate microglia function. We have also identified a commercial HPC source that can be readily differentiated to iMGLs with our protocol to study microglia biology. We demonstrate that iMGLs phagocytose a variety of neuronal substrates, including b-amyloid, brain-derived tau oligomers, and human synaptosomes, that can be used to study the influence of AD genetic risk factors, including recently identified novel TREM2 variants (Sirkis et al., 2016) on microglia function, with the potential to uncover altered microglia pathways that can guide future therapeutic targets. Because many AD-GWAS genes also suggest microglia-neuronal crosstalk (e.g., TREM2-lipids, APOE/J, CD33-sialic acid, MS4A cluster/lipids), we demonstrated that iMGLs can be studied in context with neurons and glia by examining how both rodent and human neuronal cells influence microglia phenotype and function both in vitro and in vivo. As expected, iMGLs gene profiles shift toward a neuronal-centric phenotype and respond appropriately to injury in 3D cell culture and b-amyloid plaques in AD transgenic mice brains. Together, our fully defined protocol yields highly pure microglia-like cells that provide a platform to investigate human microglia function for a broad range of CNS development, homeostatic function, and neurological disease applications. While the validation of iMGLs as microglia surrogates raised several new and exciting questions related to microglia biology in development, health, and disease, this new renewable resource will allow for those questions to be further addressed by the field.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Chemical Reagents
All cell culture flasks, reagents, supplements, cytokines, and general reagents were purchased from Thermo Fisher Scientific, unless otherwise noted.
Cell Culture
Maintenance and Culture of Human Pluripotent Stem Cells (hPSCs) All stem cell work was performed with approval from UC Irvine Human Stem Cell Research Oversight (hSCRO) and IBC committees. The use of human fibroblast and PBMC samples for iPSC reprogramming and differentiation was approved by the University of California, Irvine Institutional Review Board (IRB Protocol #2013-9561) and informed consent was obtained from all subjects. Human iPSC cell lines ADRC 2 (Male), 4 (Male), 5 (Female), 12 (Male), 14 (Male), 20 (Female), 22 (Female), 76 (Male), 85 (Female), and 86 (Female) were generated by the UCI Alzheimer's Disease Research Center (ADRC) Induced Pluripotent Stem Cell Core using non-integrating Sendai virus (Cytotune) and are available to other researchers via http://stemcells.mind.uci.edu/. iPSCs were confirmed to be sterile and karyotypically normal via G-banding (http://www.WiCell.org). Pluripotency of all lines was confirmed via (http://pluritest. org) and further confirmed using the Human Pluripotent Stem Cell Functional Identification Kit (R&D Systems), per manufacturer's instructions.
iPSCs were maintained in 6-well plates (Corning) in feeder-free conditions using growth factor-reduced Matrigel (MTG, BD Bioscience) in complete TeSR-E8 medium (STEMCELL Technologies) in a humidified incubator (5% CO 2 , 37 C). iPSCs were fed fresh media daily and passaged every 7-8 days.
Differentiation of iPSCs to Hematopoietic Progenitor Cells
Human iPSC-derived hematopoietic progenitors were generated using defined conditions with several modifications to previously published protocols (Kennedy et al., 2007; Sturgeon et al., 2014) .
iHPC Differentiation Base Medium Formulation: IMDM (50%), F12 (50%), insulin (0.02 mg/ml), holo-transferrin (0.011 mg/ml), sodium selenite (13.4 mg/ml), ethanolamine (4 mg/ml) (can use ITSG-X, 2% v/v, Thermo Fisher Scientific), L-ascorbic acid 2-Phosphate magnesium (64 mg/ml; Sigma), monothioglycerol (400 mM), PVA (10 mg/ml; Sigma), Glutamax (1X), chemically-defined lipid concentrate (1X), non-essential amino acids (NEAA; 1X), Penicillin/Streptomycin (P/S; 1% V/V). Use 0.22 mm filter.
Day (À1): iPSCs were washed with room temperature 1X DPBS (minus Ca 2+ and Mg 2+ ) once. Wash was aspirated to waste and TrypLE Select (1X; 37 C; 1 mL per 6-well) and placed in incubator (5% CO 2 , 37 C). After 3-5 min, cells were placed in cell culture hood and the side of the plate was lightly tapped for 30 s to dislodge iPSCs. After lightly tapping the plate, 1 mL of room temperature 1X DPBS (minus Ca 2+ and Mg
2+
) was added to each well. Then cells were collected into a 15 mL conical tube (Corning) using a 10 mL Stripette (Corning). Cells were centrifuged at 200 x g for 5 min at room temperature. After centrifugation, supernatant was aspirated to waste and cells were suspended in E8 medium + Y-27632 ROCK Inhibitor (RI,10 mM; R&D Systems), and gently triturated to generate a single-cell suspension, counted, and cell density adjusted to seed at 5 3 10 5 cells/cm 2 in tissue-culture treated 6-well plates. The final volume was adjusted to 1.5 mL of E8+ RI per well. Cells were cultured for 24 hr under normoxic conditions (20% O 2, 5% CO 2 , 37 C). Day (0): Cells were gently collected into a 50 mL conical tube (Corning) using 10 mL Stripette and centrifuged at 300 x g for 6 min at room temperature (all media changes will require this step using these parameters.). Media was aspirated to waste, and media was changed to basal medium complete with FGF2 (50 ng/ml), BMP4 (50 ng/ml), Activin-A (12.5 ng/ml), RI (1 mm) and LiCl (2mM) at 2 mL per well. Cells were then placed in humidified tri-gas incubator under hypoxic cell culture conditions (5%O 2, 5%CO 2, 37 C). Day (2): Cells were quickly and gently collected into a 50 mL conical using 10 mL Stripette and centrifuged. Supernatant was aspirated to waste and media was changed to pre-equilibrated (at 5%O 2, 5%CO 2, 37 C for 1 hr) base media supplemented with FGF2 (50 ng/ml) and VEGF (50 ng/ml) and returned to the hypoxia incubator.
Day (4): Media was changed to 2 mL per well with basal media containing FGF2 (50 ng/ml), VEGF (50 ng/ml), TPO (50 ng/ml), SCF (10 ng/ml), IL-6 (50 ng/ml), and IL-3 (10 ng/ml) and placed into a normoxia incubator.
Days (6 and 8): Cells were supplemented with 1ml per well of Day 4 medium. Day (10): Cells were collected and prepped for FACS (see Method Details) and CD43 + cells were isolated by FACS for iMGL differentiation. Additionally, iPSC-derived HPCs (Cellular Dynamics International) were identified as a commercial source of CD43 + progenitors. Differentiation of iHPCs to iMGLs iMGL Differentiation Base Medium: Differentiation media consists a base media: phenol-free DMEM/F12 (1:1), insulin (0.02 mg/ml), holo-transferrin (0.011 mg/ml), sodium selenite (13.4 mg/ml) (can use ITS-G, 2%v/v, Thermo Fisher Scientific), B27 (2% v/v), N2 (0.5%, v/v), monothioglycerol (200 mM), Glutamax (1X), NEAA (1X), and additional insulin (5 mg/ml; Sigma) and filtered through a 0.22 mm filter.
Day (0; or day 10 from iPSC): Isolated CD43 + iHPCs were washed using iMGL base differentiation medium and centrifuged at 300 x g for 6 min at room temperature. After centrifugation, supernatant was aspirated to waste and iHPCs were gently suspended in complete differentiation medium: M-CSF (25 ng/ml), IL-34 (100 ng/ml; PeproTech), and TGFb-1 (50 ng/ml; Militenyi) added fresh each time. Cell density was adjusted to seed at 1-2 x10 5 cells in 2 mL of complete medium per well in growth factor-reduced Matrigelcoated 6-well plates. Every two days: Each well was supplemented with 1 mL per well of complete differentiation medium. Day (12; or day 22 from iPSC): Early iMGLs were collected (300x g for 6 min at room temperature) and a 50% media change was performed.
After 25 days of microglial differentiation (35 days from iPSC), iMGLs were cultured in complete differentiation media supplemented with CD200 (100 ng/ml, Novoprotein) and CX3CL1 (100 ng/ml; PeproTech) for an additional three days. Human Adult and Fetal Microglia Isolation All studies using human tissue were approved by the McGill University institutional review board (McGill University Health Centre Ethics Board; #ANTJ2001/1). All experiments were conducted in accordance with the Helsinki Declaration. Sex of donor was either not provided or collected. Human microglia were isolated from adult brain tissue using previously described protocols (Durafourt et al., 2013) . Briefly, normal appearing cortical tissue was resected from pharmacologically intractable non-malignant cases of temporal lobe epilepsy. Tissue was cleaned extensively and mechanically dissociated. A single cell suspension was generated following gentle enzymatic digestion using trypsin and DNase prior to passing through a nylon mesh filter. Single cell suspension underwent a fickle ultracentrifugation step to remove myelin. Dissociated cells were centrifuged, counted, and plated at 2x10 6 cells/mL in MEM supplemented with heat-inactivated FBS (5%), P/S (0.1% v/v) and glutamine (0.1% v/v.) . Microglia were grown for 3 days, collected and plated at 1x10 5 cells/mL and maintained in culture for 6 days during which time cells received two treatments of TGFb (20 ng/mL) on days 3 and 5. Human fetal brain tissue was obtained from the Fetal Tissue Repository (Albert Einstein College of Medicine, Bronx, NY). Total RNA was isolated using standard Trizol (Thermo Fisher Scientific) protocols and stored at À80 C. 3D Brain-Organoid Generation Human 3D brain organoids were generated as previously described, with some modifications (Lancaster et al., 2013) . iPSCs were cultured and maintained on Vitronectin XF (STEMCELL Technologies) in 6-well tissue culture treated plates (BD Falcon) and maintained with TeSR-E8 media (STEMCELL Technologies) daily, at 37 C with 5% CO 2 . At approximately 80% confluency, iPSCs were detached from the Vitronectin XF substrate using the standard ReLeSR protocol (STEMCELL Technologies) and centrifuged, pelleted, and suspended in embryoid body (EB) media, which consists of KO DMEM/F12 (Invitrogen), KOSR (20% v/v) , Glutamax (1X), NEAA (1X), 2-Mercaptoethanol (0.1mM), bFGF (4 mg/ml), and HSA (0.1% v/v) and ROCK inhibitor (50 mM), to form EBs. Approximately 1x10 4 cells were plated per well of a standard V-bottom 96-well plate coated with Lipidure (1% v/v; AMSBio) to avoid having the EBs attach to the 96-well plate. After 4 days in EB media with bFGF (4 ng/ml) and ROCK inhibitor (50 mM), both the bFGF and ROCK inhibitor were discontinued leaving the brain organoids in basic EB media for an additional 3 days (7 days total). After the EB media phase, the EB media is replaced with neural epithelium (NE) media which consists of DMEM/F12, N2 supplement (0.1% v/v), Glutamax (1X), MEM-NEAA (0.1X), Heparin solution (0.2mg/ml; Sigma), and filtered using 0.22 mm PES filter (EMD Millipore). The brain organoids were transferred to an ultra-low attachment 24-well plate (Corning) using cut P200 pipette tips, with 1-2 EBs per well in 1 mL NE media. The EBs were neuralized in the NE media for five days, after which they were transferred into Matrigel (Corning) using a mold created from siliconized parafilm and a sterile empty P200 box. The brain organoids were kept in a 6-cm suspension petri dish with differentiation media consisting of KO DMEM/F12 (50%), Neurobasal medium (50%), N2 supplement (0.1% v/v), B27 without vitamin A supplement (0.1% v/v), Insulin solution (0.1% v/v; Sigma), 2-Mercaptoethanol (0.1mM), Glutamax (1X v/v), MEM-NEAA (1X), and Penicillin/Streptomycin (0.1% v/v). After five days of being exposed to differentiation media containing B27 without vitamin A, the differentiation media was replaced by a formulation that is identical except for the replacement of B27 without vitamin A to B27 with vitamin A; at this time point, the brain organoids are also transferred to a 125 mL spinning flask bioreactor (Corning) siliconized with Sigmacote (Sigma), where they were fed differentiation media with vitamin A weekly for 8 weeks.
After 12 weeks, Borgs were utilized for iMGL co-culture studies. Rat Cortical and Hippocampal Neuron Isolation All procedures were performed under an IUCAC approved protocol. Primary cortical and hippocampal neuron cultures were derived from embryonic rat (E18) as previously described (Loo et al., 1993) . Briefly, dissected tissue was dissociated with trypsin, triturated, and plated on 6-well plates coated with poly-L-lysine coated in NB medium (serum-free Neurobasal supplemented with 1% B27). Cells were plated at a density of 5 3 10 6 cells/ml and cells were fed once a week with 50% media change until used for assays.
PBMCs and Monocytes Isolation from Human Blood
The isolation of human monocytes and dendritic cells from de-identified human subjects was performed under IRB Protocol #2015-2437 and through the UC Irvine ICTS Blood Donor Program. Donor sex: CD14 M = 2 males, 3 females. CD16 M = 2 males, 2 females. Blood DCs were all from female donors. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using Ficoll-paque (GE Healthcare) gradient separation. In brief, blood was layered on top of Ficoll-Paque and centrifuged in swinging bucket rotator without brake (400x g, 40 min, 18 C). After centrifugation, plasma and upper layers were removed and PBMCs isolated from the interphase. Cells were then washed once with ice-cold PBS and used immediately. CD14 and CD16 monocytes were isolated via negative selection from PBMCs using the EasySep Monocyte Enrichment Kit (STEMCELL Technologies) per manufacturer's instructions. Blood dendritic cells were isolated via negative selection from PBMCs using the EasySep Human Pan-DC Pre-Enrichment Kit (STEMCELL Technologies) per manufacturer's instructions. Isolated cells were washed three times with PBS and sorted by FACS for either RNA-sequence analysis or used for further macrophage differentiation. Monocyte-Derived Macrophages Isolated monocytes (from males) were plated onto tissue culture treated 6-wells at 2 x10 6 cells/ml in RPMI-1640 media at 37 C 5% CO 2 incubator. After two hours, media was aspirated to waste and adherent monocytes washed three times with DPBS and replaced with complete media composed of RPMI-1640, FBS (10% v/v), Penicillin/streptomycin (1% v/v), Glutamax (1X). To generate MD-Mf, M-CSF (25 ng/ml) was added to wells and cells differentiated for 5 days.
METHOD DETAILS

RNA-Seq Library Construction
Cells were harvested and washed three times with DPBS and stored in RNAlater, RNA preservation solution. RNA was extracted from all cell types using RNeasy Mini Kit (QIAGEN) following manufacturer's guidelines. RNA integrity (RIN) was measured for all samples using the Bioanalzyer Agilent 2100 series. All sequencing libraries analyzed were generated from RNA samples measuring a RIN score R 9. The Illumina TruSeq mRNA stranded protocol was used to obtain poly-A mRNA from all samples. 200 ng of isolated mRNA was used to construct RNA-seq libraries. Libraries were quantified and normalized using the Library Quantification Kit from Kapa Biosystems and sequenced as paired-end 100 bp reads on the Illumina HiSeq 2500 platform.
Confocal Microscopy and Bright-Field Imaging
Immunofluorescent sections were visualized and images captured using an Olympus FX1200 confocal microscope. To avoid nonspecific bleed-through, each laser line was excited and detected independently. All images shown represent either a single confocal z-slice or z-stack. Bright-field images of cell cultures were captured on an Evos XL Cell Imaging microscope. Image analysis was performed using Olympus.
FACS and Flow Cytometer Analysis iHPCs were collected using cold (4 C) sterile filtered and degassed FACS buffer (1X DPBS, 2% BSA, and 0.05mM EDTA) spiked with human SCF (5 ng/ml). Cells were then filtered through 70 mm mesh to remove large clumps, washed with spiked FACS buffer (300 x g for 5 min 18 C), then stained (1:200) using spiked FACS buffer on ice for 1 hr in the dark using the following antibodies: anti CD34-FITC clone 561, anti CD41-PE clone HiP8, anti CD43-APC clone CD43-10G7, anti CD45-APC/Cy7 clone HI30 (Tonbo Biosciences), anti CD235a-PE/Cy7 clone HI264, and ZombieViolet live/dead stain, all from BioLegend unless noted. After staining, iHPCs were washed once with spiked FACS buffer and suspended using spiked FACS buffer (500-700 ml) and sorted utilizing the BD FACSARIA Fusion (BD Biosciences). Sorted cells were collected in cold basal iHPC differentiation medium spiked with SCF (10 ng/ml). Collected CD43+ iHPCs were then plated for iMGL differentiation as mentioned above. iMGLs were suspended in FACS buffer and incubated with human Fc block (BD Bioscience) for 15 min at 4 C. For detection of microglial surface markers, cells were stained with anti CD11b-FITC clone ICRF44, anti CD45-APC/Cy7 clone HI30 (Tonbo Biosciences), anti CX3CR1-APC clone 2A9-1, anti CD115-PE clone 9-4D, and anti CD117-PerCP-Cy5.5 clone 104D2, ZombieViolet live/dead stain, all from BioLegend. Cells were sorted on a FACS Aria II, FACS Aria Fusion (BD Biosciences) and data analyzed with FlowJo software (FlowJo).
Cytospin and May-Grunwald Giemsa Stain 1x10 5 cells were suspended in FACS buffer (100 ml) and added to Shandon glass slides (Biomedical Polymers) and assembled in a cytology funnel apparatus. Assembled slides containing cells were loaded in a cytospin instrument and centrifuged (500 rpm, 5 min). Slides were allowed to air-dry for two minutes and immediately stained in May-Grunwald stain (100%; Sigma) for 5 min. Next, slides were washed in PBS for 1.5 min and immediately placed in Giemsa stain (4%; Sigma) for 20 min at room temperature. Slides were washed in double-distilled water 6 times and allowed to air-dry for 10 min. Slides were preserved using glass coverslips and permount (Sigma).
RNA Isolation and qPCR Analysis
Cells were stored in RNAlater stabilizing reagent and RNA was isolated using QIAGEN RNeasy Mini Kit (Valencia, CA) following manufacturer's guidelines. qPCR analysis was performed using a ViiA 7 Real-Time PCR System and using Taqman qPCR primers. Analysis of AD-GWAS genes utilized a custom Taqman Low Density Array card using the primers described below.
iMGL Co-culture with Rat Neurons Rat hippocampal or cortical neurons were cultured for 21 days with 50% media change every 3-4 days. iMGLs were cultured with neurons at a 1:5 ratio (1 x10 6 iMGL to 5 3 10 6 neurons) in 50% iMGL and 50% NB medium. After 3 days, iMGLs were collected for RNA isolation.
iMGL Transplantation in MITRG and Rag-5xfAD Brains All animal procedures were performed in accordance with NIH and University of California guidelines approved IAUC protocols (IAUC #2011-3004). MITRG mice were purchased from Jax (The Jackson Laboratory, #017711) and have been previously characterized (Rongvaux et al., 2014) . MITRG mice allow for xenotransplantation and is designed to support human myeloid engraftment. iMGLs were harvested at day 38 and suspended in injection buffer: 1X HBSS with M-CSF (10 ng/ml), IL-34 (50 ng/ml), and TGFb-1 (25 ng/ml). iMGLs were delivered using stereotactic surgery as previously described (Blurton-Jones et al., 2009) using the following coordinates; AP: À0.6, ML: ± 2.0, DV: À1.65. Brains were collected from mice at day 60 post-transplantation per established protocols (BlurtonJones et al., 2009 ). Rag-5xfAD mice were generated in this lab and previously characterized (Marsh et al., 2016) . Rag-5xfAD mice display robust beta-amyloid pathology and allow for xenotransplantation of human cells. iMGLs were transplanted into the hippocampi using the following coordinates; AP: À2.06, ML: ± 1.75, DV: À1.95. After transplantation mice were killed and brains collected using previously established protocol. Briefly, mice were anesthetized using sodium-barbiturate and perfused through the leftventricle with cold 1X HBSS for 4 min. Perfused mice were decapitated and brain extracted and dropped-fixed in PFA (4% w/v) for 48 hr at 4 C. Brains were then washed 3 times with PBS and sunk in sucrose (30% w/v) solution for 48 hr before coronal sectioning (40 mm) using a microtome (Leica). Free-floating sections were stored in PBS sodium azide (0.05%) solution at 4 C until IHC was performed.
Immunocytochemistry and Immunohistochemistry
For ICC, cells were washed three times with DPBS (1X) and fixed with cold PFA (4% w/v) for 20 min at room temperature followed by three washes with PBS (1X). Cells were blocked with blocking solution (1X PBS, 5% goat or donkey serum, 0.2% Triton X-100) for 1 hr at room temperature. ICC primary antibodies were added at respective dilutions (see below) in blocking solution and placed at 4 C overnight. The next day, cells were washed 3 times with PBS for 5 min and stained with Alexa Fluor conjugated secondary antibodies at 1:400 for 1 hr at room temperature in the dark. After secondary staining, cells were washed 3 times with PBS and coverslipped with DAPI-counterstain mounting media (Fluoromount, southern Biotech). For BORG IHC, tissue were collected and dropped-fixed in PFA (4% w/v) for 30 min at room temperature and then washed three times with PBS. BORGs were then placed in sucrose solution (30% w/v) overnight before being embedded in O.C.T (Tissue-Tek). Embedded tissue was sectioned at 20 mm using a cryostat and mounted slides were stored at À20 C until staining. For BORG staining, mounted tissue was removed from storage and warmed by placing at room temperature for 30 min. Tissue were rehydrated and washed with room temperature PBS (1X) 3 times for 5 min. Heat-mediated antigen retrieval was performed by using Citrate Buffer (10mM Citrate, 0.05% Tween 20, pH = 6.0) at 97 C for 20 min and then allowed to cool to room temperature. After antigen retrieval, slides were washed three times with PBS. Slides were then washed once in PBS-A solution (1X PBS with 0.1% Triton X-100) for 15 min. Tissue was blocked using PBS-B solution (PBS-A, 0.2% BSA, and 1.5% goat or donkey serum) for 1 hr at room temperature. After block, primary antibodies were added to PBS-B solution (250-350 ml/ slide) at appropriate dilutions (see below) and incubated overnight at room temperature. The next day, slides were washed with PBS-A solution 3 times for 5 min each. Tissue were blocked for 1 hr using PBS-B solution at room temperature. After block, slides were incubated with Alexa Fluor conjugated secondary antibodies (all at 1:500) and Hoechst stain (1X) in PBS-B (for 250-300 ml/slide) for 2 hr at room temperature in the dark. After secondary staining, slides were washed 5 times with PBS for 5 min. Slides were coverslipped using fluoromount (Southern Biotech). For mouse brain IHC, brains were collected, fixed, and processed as mentioned above. Free-floating sections were blocked in blocking solution (1X PBS, 0.2% Triton X-100, and 10% goat serum) for 1 hr at room temperature with gentle shaking. For human TMEM119 staining, heat mediated antigen retrieval was performed prior to blocking, as performed previously (Bennett et al., 2016) . Free-floating tissue antigen retrieval was performed by placing floating sections in a 1.5 mL micro centrifuge tube containing 1 mL of Citrate Buffer solution and placing in a pre-heated temperature block set at 100 C. Tissue was heated for 10 min at 100 C then removed and allowed to come to room temperature for 20 min before washing with PBS 3 times for 5 min and then proceeding with blocking step. For AD mouse brain staining of amyloid plaques, floating sections were placed in 1X Amylo-Glo RTD (Biosensis) staining solution for 10 min at room temperature without shaking. After staining, sections were washed in PBS 3 times for 5 min each and briefly rinsed in MiliQ DI water before being placed
